Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.40 |
| ▸ | CPT1A | P50416 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR1E | P28566 | 1/20 | 0.38 |
| ▸ | HTR1F | P30939 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7026821 | 1.00 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2ARHPGD | |
| SCHEMBL4292890 | 1.00 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2ARHPGD | |
| SCHEMBL4290384 | 0.83 | SMN1; SMN2 (0.40) | NPC1RAB9ASMN1; SMN2HRH3CYP2D6 | |
| SCHEMBL7019971 | 0.81 | KDM1A (0.54) | RAB9AHRH3ALDH1A1LMNARECQL | |
| SCHEMBL4288425 | 0.81 | KDM1A (0.54) | RAB9AHRH3ALDH1A1LMNARECQL | |
| SCHEMBL4288434 | 0.81 | KDM1A (0.54) | RAB9AHRH3ALDH1A1LMNARECQL | |
| SCHEMBL4288431 | 0.81 | KDM1A (0.54) | RAB9AHRH3ALDH1A1LMNARECQL | |
| SCHEMBL4295426 | 0.80 | HRH3 (0.42) | NPC1RAB9ASMN1; SMN2HRH3CYP2D6 | |
| SCHEMBL4295422 | 0.80 | HRH3 (0.42) | NPC1RAB9ASMN1; SMN2HRH3CYP2D6 | |
| SCHEMBL4295431 | 0.80 | HRH3 (0.42) | NPC1RAB9ASMN1; SMN2HRH3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | APODACA RICHARD | 2009-10-22 | — | — | US | claimed |
| US-20050288323-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | APODACA RICHARD | 2005-12-29 | — | — | US | claimed |
| US-20040167336-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | APODACA RICHARD (US) | 2004-08-26 | — | — | US | claimed |
| EP-1326863-A2 | OCTAHYDRO-INDOLIZINES AND QUINOLIZINES AND HEXAHYDRO-PYRROLIZINES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-07-16 | — | — | EP | claimed |
| US-20030013733-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-01-16 | — | — | US | claimed |
| WO-2002024695-A2 | OCTAHYDRO-INDOLIZINES AND QUINOLIZINES AND HEXAHYDRO-PYRROLIZINES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-28 | — | — | WO | claimed |
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | APODACA RICHARD | 2009-10-22 | — | — | US | disclosed |
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | APODACA RICHARD | 2009-10-22 | — | — | US | disclosed |
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | APODACA RICHARD | 2009-10-22 | — | — | US | disclosed |
| US-20050288323-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | APODACA RICHARD | 2005-12-29 | — | — | US | disclosed |
| US-20040167336-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | APODACA RICHARD (US) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288323-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | HRH4, HNMT, HRH1 | NPC1 1739/4885RAB9A 2361/4885SMN1; SMN2 4452/4885 |
| US-20030013733-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | HRH4, HNMT, HRH1 | NPC1 1739/4885RAB9A 2361/4885SMN1; SMN2 4452/4885 |
| US-20040167336-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | HRH4, HNMT, HRH1 | NPC1 1739/4885RAB9A 2361/4885SMN1; SMN2 4452/4885 |
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | HRH4, HNMT, HRH1 | NPC1 1655/4885RAB9A 2371/4885SMN1; SMN2 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.